You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ABC DLBCL

Showing 1 - 25 of 831
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)

Active, not recruiting
Has Results
  • Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
  • Los Angeles, California
  • +6 more
Dec 1, 2022

Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type DLBCL (ABC-DLBCL), Mantle Cell Lymphoma (MCL) Trial in Indianapolis, Spokane

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • +4 more
  • Indianapolis, Indiana
  • +1 more
Jul 12, 2022

Non-GCB/ABC DLBCL, With and Without MyD88 and/or CD79B Mutations Trial in Cleveland, Toledo (Mivavotinib)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • With and Without MyD88 and/or CD79B Mutations
  • Evanston, Illinois
  • +6 more
Dec 12, 2022

Non-GCB/ABC DLBCL Trial in Suzhou (Zanubrutinib, Rituximab, Cyclophosphamide)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 12, 2021

Non-GCB/ABC DLBCL, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (PD-1 Antibody, Lenalidomide)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • +5 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 12, 2021

Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (lenalidomide, Placebo, Rituximab)

Completed
Has Results
  • Lymphoma, Large B-Cell, Diffuse
  • Fayetteville, Arkansas
  • +431 more
Nov 17, 2022

Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL) Trial in United States (Cobomarsen)

Completed
  • Cutaneous T-cell Lymphoma (CTCL)
  • +4 more
  • Duarte, California
  • +18 more
Nov 19, 2020

Diffuse Large B-cell Lymphoma Trial in Switzerland (Acalabrutinib)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Bergamo, Italy
  • +16 more
Jan 17, 2023

Diffuse Large B-cell Lymphoma(DLBCL) Trial in Shanghai (Zanubrutinib + R-CHOP)

Recruiting
  • Diffuse Large B-cell Lymphoma(DLBCL)
  • Zanubrutinib + R-CHOP
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 10, 2022

Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy Trial in United States (Emavusertib, ibrutinib)

Recruiting
  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy
  • Phoenix, Arizona
  • +10 more
Feb 1, 2023

Predict CNS Involvement in Diffuse Large B-Cell Lymphoma:Danish

Completed
  • Diffuse Large B Cell Lymphoma
  • +2 more
    • (no location specified)
    Dec 13, 2021

    Diffuse Large B Cell Lymphoma Trial in Colchester, Canterbury, Nottingham (R-CHOP, R-CHOP + acalabrutinib)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Colchester, Essex, United Kingdom
    • +32 more
    Oct 25, 2022

    Diffuse Large B Cell Lymphoma Trial in Berlin (Ibrutinib and Bortezomib + R-CHOP)

    Active, not recruiting
    • Diffuse Large B Cell Lymphoma
    • Ibrutinib and Bortezomib + R-CHOP
    • Berlin, Germany
      Charité - Universitätsmedizin Berlin, Hematology, Oncology and T
    Aug 10, 2022

    Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

    Suspended
    • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
    • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jul 6, 2022

    Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation Trial in Zhengzhou (Rituximab, Zanubrutinib,

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Zhengzhou, Henan, China
      Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
    Jan 22, 2022

    Mixed Molecular Clinical Index in Diffuse Large B-cell Lymphoma

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • molecular characterization
    • Meldola, FC, Italy
    • +3 more
    Feb 25, 2021

    CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

    Recruiting
    • Central Nervous System Lymphoma
    • Secondary Central Nervous System Lymphoma
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (Durvalumab, Rituximab, Doxorubicin)

    Completed
    Has Results
    • Lymphoma, Large B-Cell, Diffuse
    • Gilbert, Arizona
    • +18 more
    Aug 19, 2022

    Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

    Recruiting
    • Grade 3a Follicular Lymphoma
    • +14 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Atlanta, Georgia
    • +1 more
    May 31, 2022

    CD79 Mutant or ABC-subtype DLBCL Trial in Worldwide (AEB071, Everolimus)

    Completed
    • CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
    • Saint Louis, Missouri
    • +14 more
    Dec 16, 2020

    DLBCL Trial in Spain (Ibrutinib, Rituximab, Gemcitabine)

    Unknown status
    • Diffuse Large B-Cell Lymphoma
    • Oviedo, Asturias, Spain
    • +16 more
    Aug 12, 2020

    DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Apr 10, 2023

    Including miRNA-based Tumor Signatures in Diffuse Large B Cell

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • Relapsed Non-Hodgkin Lymphoma
    • no intervention (observational study)
    • Napoli, Italy
    • +2 more
    Feb 17, 2023

    TNBC - Triple-Negative Breast Cancer Trial (A1:SG with SHR3680, A2:SG, B1:SG with SHR1210)

    Not yet recruiting
    • TNBC - Triple-Negative Breast Cancer
    • A1:SG with SHR3680
    • +7 more
    • (no location specified)
    Jun 23, 2023

    Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)

    Not yet recruiting
    • Hormone Receptor-positive Advanced Breast Cancer
    • (no location specified)
    Apr 12, 2023